latest update:
[TrialBase DB]

trial summary · NCT07578077

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Mantle Cell Lymphoma, sponsored by City of Hope Medical Center. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07578077phase PHASE1/PHASE2enrollment 58start 2026-12-21

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase I/II trial tests the safety, side effects, best dose and effectiveness of golcadomide in combination with rituximab in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide in combination with rituximab may better treat patients with relapsed or refractory mantle cell lymphoma.

Source record: https://clinicaltrials.gov/study/NCT07578077

Facts

registry idNCT07578077
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionRecurrent Mantle Cell Lymphoma
sponsorCity of Hope Medical Center
sponsor classOTHER
enrollment58
start date2026-12-21
primary completion2030-04-21
completion2030-04-21
results postednot reported

Conditions

  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma

Interventions

  • Biopsy Procedure
  • Biospecimen Collection
  • Bone Marrow Biopsy
  • Computed Tomography
  • Golcadomide
  • Positron Emission Tomography
  • Rituximab

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG, PROCEDURE

Work with this record